Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


08.07.2019

1 Ann Surg Oncol
1 Anticancer Res
3 Br J Dermatol
2 Clin Cancer Res
1 J Am Acad Dermatol
1 J Surg Oncol
1 Lancet Oncol
1 Melanoma Res
1 N Engl J Med
1 Nat Med
1 Oncogene


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. SONG Y, Tieniber AD, Gimotty PA, Mitchell TC, et al
    Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies.
    Ann Surg Oncol. 2019 Jul 3. pii: 10.1245/s10434-019-07599.
    PubMed     Text format     Abstract available


    Anticancer Res

  2. MARJANSKA A, Galazka P, Marjanski M, Wysocki M, et al
    Efficacy and Toxicity of Pembrolizumab in Pediatric Metastatic Recurrent Melanoma.
    Anticancer Res. 2019;39:3945-3947.
    PubMed     Text format     Abstract available


    Br J Dermatol

  3. ARMSTRONG J
    Bioenergetic cellular index: a clinical biomarker to identify metabolic adaption in melanoma?
    Br J Dermatol. 2019;181:15-16.
    PubMed     Text format    

  4. FRANKE V
    Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma.
    Br J Dermatol. 2019;181:20-21.
    PubMed     Text format    

  5. TOLAND AE
    POT1 pathogenic variants: not all telomere pathway genes are equal in risk of hereditary cutaneous melanoma.
    Br J Dermatol. 2019;181:14-15.
    PubMed     Text format    


    Clin Cancer Res

  6. LUKE JJ, Bao R, Sweis RF, Spranger S, et al
    WNT/beta-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
    Clin Cancer Res. 2019;25:3074-3083.
    PubMed     Text format     Abstract available

  7. GOFF SL, Rosenberg SA
    BRAF Inhibition: Bridge or Boost to T-cell Therapy?
    Clin Cancer Res. 2019;25:2682-2684.
    PubMed     Text format     Abstract available


    J Am Acad Dermatol

  8. CUI X, Wei R, Gong L, Qi R, et al
    Assessing the effectiveness of artificial intelligence methods for melanoma:A retrospective review.
    J Am Acad Dermatol. 2019 Jun 27. pii: S0190-9622(19)31041.
    PubMed     Text format     Abstract available


    J Surg Oncol

  9. SONG Y, Bruce AN, Fraker DL, Karakousis GC, et al
    Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies.
    J Surg Oncol. 2019 Jul 2. doi: 10.1002/jso.25600.
    PubMed     Text format     Abstract available


    Lancet Oncol

  10. AMARIA RN, Menzies AM, Burton EM, Scolyer RA, et al
    Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.
    Lancet Oncol. 2019;20:e378-e389.
    PubMed     Text format     Abstract available


    Melanoma Res

  11. GUTIERREZ-CASTANEDA LD, Nova JA, Tovar-Parra JD
    Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.
    Melanoma Res. 2019 Jul 3. doi: 10.1097/CMR.0000000000000628.
    PubMed     Text format     Abstract available


    N Engl J Med

  12. ESFAHANI K, Buhlaiga N, Thebault P, Lapointe R, et al
    Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
    N Engl J Med. 2019;380:2375-2376.
    PubMed     Text format    


    Nat Med

  13. RIBAS A, Lawrence D, Atkinson V, Agarwal S, et al
    Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
    Nat Med. 2019 Jul 2. pii: 10.1038/s41591-019-0535.
    PubMed     Text format     Abstract available


    Oncogene

  14. RATHORE M, Girard C, Ohanna M, Tichet M, et al
    Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappaB signaling pathway.
    Oncogene. 2019 Jun 28. pii: 10.1038/s41388-019-0848.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: